A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 139, doi. 10.1007/s10637-006-9019-2
- By:
- Publication type:
- Article
Works matching IS 01676997 AND DT 2007 AND VI 25 AND IP 2
Results: 12
1
2
Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 161, doi. 10.1007/s10637-006-9007-6
- By:
- Publication type:
- Article
3
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 131
- By:
- Publication type:
- Article
4
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 173, doi. 10.1007/s10637-006-9010-y
- By:
- Publication type:
- Article
5
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 123, doi. 10.1007/s10637-006-9016-5
- By:
- Publication type:
- Article
6
The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 115
- By:
- Publication type:
- Article
7
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 107
- By:
- Publication type:
- Article
8
The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 95
- By:
- Publication type:
- Article
9
A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 155, doi. 10.1007/s10637-006-9002-y
- By:
- Publication type:
- Article
10
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 181, doi. 10.1007/s10637-006-9009-4
- By:
- Publication type:
- Article
11
A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 147, doi. 10.1007/s10637-006-9024-5
- By:
- Publication type:
- Article
12
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.
- Published in:
- Investigational New Drugs, 2007, v. 25, n. 2, p. 165, doi. 10.1007/s10637-006-9011-x
- By:
- Publication type:
- Article